Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04136353 |
| Title | Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP) |
| Acronym | DASL-HiCaP |
| Recruitment | Active, not recruiting |
| Gender | male |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | University of Sydney |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | NZL | IRL | GBR | CAN | AUS |